TG Therapeutics, Inc. (TGTX) stock
TGTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/307% above fair value
$63.34−1.54 (-2.37%)
Close on Nov 20, 2026Market cap $9.70BP/E 23.1Yield –
TG Therapeutics net income
Net income is the profit left for shareholders after every expense, interest and tax.
TG Therapeutics's net income for the twelve months ending Jun 30, 2026 was $441.49M, up 630.2% year over year. For fiscal 2025 it was $447.18M, up 1812.4% from the year before. The highest annual figure on record is $447.18M in fiscal 2025.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $447.18M | +1812.4% |
| FY2024 | Dec 31, 2024 | $23.38M | +84.5% |
| FY2023 | Dec 31, 2023 | $12.67M | – |
| FY2022 | Dec 31, 2022 | -$223.81M | – |
| FY2021 | Dec 31, 2021 | -$348.10M | – |
| FY2013 | Dec 31, 2013 | -$20.48M | – |
| FY2012 | Dec 31, 2012 | -$18.07M | – |
| FY2011 | Dec 31, 2011 | -$853.07K | -236.8% |
| FY2010 | Dec 31, 2010 | $623.65K | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $7.78M | -72.4% |
| Q1 FY2026 | Mar 31, 2026 | $19.78M | +290.8% |
| Q4 FY2025 | Dec 31, 2025 | $23.04M | -1.3% |
| Q3 FY2025 | Sep 30, 2025 | $390.90M | +9974.6% |
| Q2 FY2025 | Jun 30, 2025 | $28.19M | +309.8% |
| Q1 FY2025 | Mar 31, 2025 | $5.06M | – |
| Q4 FY2024 | Dec 31, 2024 | $23.33M | – |
| Q3 FY2024 | Sep 30, 2024 | $3.88M | -96.6% |
| Q2 FY2024 | Jun 30, 2024 | $6.88M | – |
| Q1 FY2024 | Mar 31, 2024 | -$10.71M | – |
| Q4 FY2023 | Dec 31, 2023 | -$14.42M | – |
| Q3 FY2023 | Sep 30, 2023 | $113.93M | – |
| Q2 FY2023 | Jun 30, 2023 | -$47.61M | – |
| Q1 FY2023 | Mar 31, 2023 | -$39.23M | – |
| Q4 FY2022 | Dec 31, 2022 | -$78.47M | – |
| Q3 FY2022 | Sep 30, 2022 | -$35.82M | – |
| Q2 FY2022 | Jun 30, 2022 | -$40.51M | – |
| Q1 FY2022 | Mar 31, 2022 | -$69.01M | – |
| Q4 FY2019 | Dec 31, 2019 | -$39.57M | – |
| Q3 FY2019 | Sep 30, 2019 | -$61.93M | – |
| Q2 FY2019 | Jun 30, 2019 | -$36.21M | – |
| Q1 FY2019 | Mar 31, 2019 | -$35.16M | – |
| Q4 FY2018 | Dec 31, 2018 | -$53.86M | – |
| Q3 FY2018 | Sep 30, 2018 | -$33.95M | – |
| Q2 FY2018 | Jun 30, 2018 | -$44.14M | – |
| Q1 FY2018 | Mar 31, 2018 | -$41.53M | – |
| Q4 FY2017 | Dec 31, 2017 | -$30.86M | – |
| Q3 FY2017 | Sep 30, 2017 | -$31.54M | – |
| Q2 FY2017 | Jun 30, 2017 | -$28.35M | – |
| Q1 FY2017 | Mar 31, 2017 | -$27.73M | – |
| Q4 FY2016 | Dec 31, 2016 | -$23.67M | – |
| Q3 FY2016 | Sep 30, 2016 | -$24.83M | – |
See a number that looks wrong?